Metastatic Brain Tumor Patients Under 50 Show Improved Survival Rates with Stereotactic Radiosurgery

A recent study published in the International Journal of Radiation Oncology • Biology • Physics, the official journal of the American Society for Radiation Oncology (ASTRO), found that cancer patients with limited brain metastases who are under 50 years old could benefit from stereotactic radiosurgery (SRS) without whole brain radiation therapy (WBRT). 

The study, “Phase 3 Trials of Stereotactic Radiation Surgery With or Without Whole-Brain Radiation Therapy for 1 to 4 Brain Metastases: Individual Patient Data Meta-Analysis,” analyzed patient data from the three largest randomized clinical trials of SRS and WBRT conducted to-date.  For patients under the age of 50 who received SRS alone, survival was improved by 13 percentage points when compared to those patients under the age of 50 who received both SRS and WBRT. 

Lead author of the study Dr. Arjun Sahgal explained, “We expected to see a survival advantage favoring combined therapy of SRS and WBRT.  However, these data clearly demonstrate the benefit for SRS alone to improve survival for our younger patients with limited brain metastases.” 

Illinois CyberKnife has extensive experience treating primary brain tumors and brain metastases with the CyberKnife® Robotic Radiosurgery System.  CyberKnife is a painless, non-invasive alternative to surgery for the treatment of both cancerous and non-cancerous tumors.  The treatment – which delivers beams of high dose radiation to tumors with extreme accuracy – offers new hope to patients worldwide. 

 For more information about Illinois CyberKnife, or to see if you or a loved one is a candidate for CyberKnife treatment, please contact us by clicking here